A brief male sexual function inventory for urology.
ABSTRACT To develop a brief questionnaire to measure male sexual function.
An initial set of questions was refined and reduced through cognitive testing and two serial validation studies. In each study, men were recruited from a sexual dysfunction clinic and a general medicine practice to complete the instrument. Test-retest reliabilities, internal consistencies, and construct validities were examined.
The final instrument covers sexual drive (two items), erection (three items), ejaculation (two items), perceptions of problems in each area (three items), and overall satisfaction (one item). Psychometric performance was generally very satisfactory, although self-assessments of ejaculate volume are problematic. Translations have been developed and pilot tested in a number of languages.
The Brief Sexual Function Inventory may be useful for measuring male sexual function in practice and research.
- SourceAvailable from: Peter B Gray[Show abstract] [Hide abstract]
ABSTRACT: While paternal investment is a defining feature of human behavioral biology, it is also considerably variable, with previous research on African Caribbean fatherhood pointing to a high prevalence of visiting relationships and blended families within which children are raised. The aims of the present study were to characterize key patterns of paternal behavior and to test three hypotheses concerning variation in fatherhood in the Caribbean island of St. Kitts. One hundred two fathers 21–40 years of age completed a questionnaire providing sociodemographic, partnership and paternal data. The sample consisted of working fathers expressing generally favorable paternal attitudes and investments in a relatively low-fertility context. Results revealed key ways in which relationship dynamics structure paternal outcomes, and differences in biological and stepfathering subject to both between- and within-subject analyses.Fathering A Journal of Theory Research and Practice about Men as Fathers 05/2015; 13(1):18-35. DOI:10.3149/fth.1301.18
- [Show abstract] [Hide abstract]
ABSTRACT: In elderly men, benign prostatic hyperplasia (BPH) is a major risk factor for sexual dysfunctions (SDys). Additionally, the standard treatments for BPH symptoms, alpha blockers and 5-alpha-reductase inhibitors, cause SDys themselves. Preparations from saw palmetto berries are an efficacious and well-tolerated symptomatic treatment for mild to moderate BPH and have traditionally been used to treat SDys. We conducted an open multicentric clinical pilot trial to investigate whether the saw palmetto berry preparation Prostasan® influenced BPH symptoms and SDys. Eighty-two patients participated in the 8-week trial, taking one capsule of 320 mg saw palmetto extract daily. At the end of the treatment, the International Prostate Symptom Score was reduced from 14.4 ± 4.7 to 6.9 ± 5.2 (p < 0.0001); SDys measured with the brief Sexual Function Inventory improved from 22.4 ± 7.2 to 31.4 ± 9.2 (p < 0.0001), and the Urolife BPH QoL-9 sex total improved from 137.3 ± 47.9 to 195.0 ± 56.3 (p < 0.0001). Investigators' and patients' assessments confirmed the good efficacy, and treatment was very well tolerated and accepted by the patients. Correlation analyses confirmed the relationship between improved BPH symptoms and reduced SDys. This was the first trial with saw palmetto to show improvement in BPH symptoms and SDys as well. [Corrections made here after initial online publication.] Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 02/2013; 27(2). DOI:10.1002/ptr.4696 · 2.40 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Testis cancer is a disease that directly affects a man's sense of masculinity and involves treatments compromising sexual function. The aim of this study was to investigate the prevalence of sexual dysfunction and the influence of chronic pain on sexuality in long-term testis cancer survivors. Thus, we examined 539 patients after they had one testis removed because of a testicular germ cell tumor. Having completed oncologic therapy, all patients received a detailed questionnaire asking about the occurrence and clinical presentation of testis pain before and after orchiectomy. In addition, items from the abridged International Index of Erectile Function and Brief Sexual Function Inventory were used to gain precise information on individual sexual function. Overall, 34.5% of our testicular cancer survivors complained of reduced sexual desire, and sexual activity was reduced in 41.6%. Erectile dysfunction was present in up to 31.5% of patients. In 24.4%, the ability to maintain an erection during intercourse was impaired. Ejaculatory disorders (premature, delayed, retrograde, or anejaculation) occurred in 84.9% of our testis cancer survivors. A total of 32.4% of our participants experienced a reduced intensity of orgasm, and 95.4% experienced reduced overall sexual satisfaction. There was a significant correlation between the occurrence of chronic pain symptoms and the relative frequency and intensity of erectile dysfunction, inability to maintain an erection, ejaculation disorders, and reduced intensity of orgasm. In conclusion, chronic pain has a negative impact on sexuality in testis cancer survivors.Journal of Andrology 04/2011; 33(5):886-93. DOI:10.2164/jandrol.110.012500 · 1.69 Impact Factor